Skip to main content
Hanmi Pharm. Co., Ltd. logo

Hanmi Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 128940 ISIN · KR7128940004 LEI · 988400PP10VZVUOFE672 KO Manufacturing
Open in API
Filings indexed 509 across all filing types
Latest filing 2026-05-22 Director's Dealing
Country KR South Korea
Listing KO 128940

About Hanmi Pharm. Co., Ltd.

https://www.hanmipharm.com/

Hanmi Pharm. Co., Ltd. is a research-oriented biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products. Its portfolio includes prescription drugs, over-the-counter (OTC) medicines, and raw materials. The company dedicates a significant portion of its revenue to in-house research and development, creating a robust pipeline of innovative therapies. A key unique selling point is its proprietary LAPSCOVERY platform technology, which is used to develop long-acting biologics. Hanmi's R&D efforts are concentrated on key therapeutic areas, including metabolic diseases, oncology, and rare diseases. The company actively collaborates with global partners to advance its clinical programs and bring novel treatments to the market.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a statutory Korean regulatory filing titled “Report on the Ownership of Certain Securities by Officers and Major Shareholders” submitted to the Financial Services Commission and Korea Exchange. It details insider shareholdings and the daily changes (acquisitions/disposals) by the National Pension Service (an institutional investor), including precise share counts, dates, and transaction types. This is a classic insider share transaction and holdings report (director’s dealing).
2026-05-22 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure of a single sale and supply contract (Hanmi Pharmaceutical’s contract details, amounts, counterparties, and terms). It does not contain financial statements or executive management details, nor is it an earnings release or M&A filing. This is a general regulatory announcement of a contract award rather than a formal report itself, so it falls into the fallback category of Regulatory Filings (RNS).
2026-05-21 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제17기 1분기)” covering the period Jan 1 2026 to Mar 31 2026 and contains extensive tables of quarterly financial data (revenues by product, segment information, capacity and production figures, risk management, etc.). It is the full interim/quarterly report itself (not a short notice or certification), matching the definition for an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming Investor Relations (IR) event, specifically a corporate presentation or roadshow for institutional investors. It includes the date, location, participants, purpose, and a note that the presentation materials will be posted on the company's website prior to the event. The document does not contain actual financial statements or detailed financial analysis, but rather serves as a notice or invitation for the IR event. Therefore, it fits the category of an Investor Presentation announcement rather than the presentation itself or a financial report.
2026-04-30 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming Investor Relations (IR) event, specifically a non-deal roadshow with institutional investors. It includes the date, location, participants, purpose, and a note that IR materials will be posted on the company's website prior to the event. The document does not contain actual financial statements or detailed financial analysis, but rather serves as a notice of the event and availability of materials. According to the classification rules, such announcements about investor presentations or roadshows fall under the category 'Investor Presentation (IP)'. The document length is short and it is clearly an announcement of an event rather than the event materials themselves, so it is not a report publication announcement (RPA). Therefore, the correct classification is 'IP' with high confidence.
2026-04-30 Korean
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a notification regarding the appointment, dismissal, or mid-term resignation of outside directors (사외이사) of Hanmi Pharmaceutical Co., Ltd. It includes details about the correction of a previous filing, dates of appointment, and confirmation from a regulatory ethics committee. The document is a formal announcement of changes in the company's board of directors, specifically outside directors. It does not contain financial data, audit information, or detailed reports but is focused on management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a direct notification of board changes.
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.